地舒单抗与唑来膦酸在不同肾功能谱下的低钙血症及其他骨矿物质紊乱风险:一项目标试验模拟
该观察性研究纳入瑞典斯德哥尔摩50岁以上起始地舒单抗(n=5,085)或唑来膦酸(n=3,599)的患者,采用目标试验模拟比较低钙血症、继发性甲状旁腺功能亢进(SHPT)和低磷血症风险。地舒单抗组上述事件发生率均高于唑来膦酸组,且主要发生于治疗前2周,风险随肾功能下降而增加,尤其限于eGFR<60 mL/min/1.73 m2者。
要点
- 地舒单抗较唑来膦酸增加低钙血症、SHPT和低磷血症风险,多发生于起始治疗2周内。
- eGFR<60 mL/min/1.73 m2者上述绝对风险差更大,不良事件主要限于该人群。
- 中重度CKD患者使用地舒单抗应尤其重视起始治疗后的钙磷及PTH监测。
核心结论
- 与唑来膦酸相比,地舒单抗与更高的低钙血症、SHPT和低磷血症风险相关,尤其在中重度CKD患者中。
研究设计与样本
- 观察性研究,采用新使用者设计与活性对照,纳入2011-2021年瑞典斯德哥尔摩50岁及以上起始地舒单抗(n=5,085)或唑来膦酸(n=3,599)的患者。
主要发现
- 地舒单抗组低钙血症发生率高于唑来膦酸组(HR 2.10 [95% CI 1.28-4.33];RD 0.72% [95% CI 0.26-1.18])。
- 地舒单抗组SHPT发生率更高(HR 2.85 [95% CI 1.94-5.48];RD 1.33% [95% CI 0.91-1.85])。
- 地舒单抗组低磷血症发生率更高(HR 1.96 [95% CI 1.30-3.38];RD 0.85% [95% CI 0.33-1.38]),主要发生于治疗前2周。
- eGFR<60 vs ≥60 mL/min/1.73 m2者低钙血症RD为2.12% vs 0.19%(交互P=0.04),SHPT RD为4.84% vs 0.03%(交互P<0.001)。
- 低磷血症RD在低eGFR层数值更高,但未见乘法交互(交互P=0.1)。
关键数值与推荐
- 结局评估窗口为发药后180天内。
临床怎么用
- 中重度CKD患者使用地舒单抗时,应尤其重视起始治疗后(特别是前2周)的钙、磷及PTH监测。
局限性
- 观察性研究存在残余混杂。
- 结果可能不适用于其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Denosumab, an osteoporosis medication, may induce hypocalcemia, secondary hyperparathyroidism (SHPT), and hypophosphatemia. We studied these risks compared with zoledronate and whether the risks differ based on underlying kidney function. STUDY DESIGN: Observational study, new-user design with active comparator. SETTING & PARTICIPANTS: Patients aged 50 year or older initiating denosumab (n = 5,085) or zoledronate (n = 3,599) in Stockholm, Sweden (2011-2021). EXPOSURE: Denosumab or zoledronate initiation. OUTCOME: Hypocalcemia, with secondary outcomes of SHPT and hypophosphatemia assessed within 180 days of dispensing of study medications. ANALYTICAL APPROACH: Cox regression to estimate hazard ratios (HRs), Aalen-Johansen estimators to compute absolute risks (ARs) and risk differences (RDs), and splines to explore effect modification by baseline estimated glomerular filtration rate (eGFR). RESULTS: Twenty-five percent of the study population had eGFR < 60 mL/min/1.73 m2 (chronic kidney disease [CKD] stage 3a [15%] and 3b [8%]). Compared with zoledronate, denosumab initiation was associated with higher rates of hypocalcemia (HR, 2.10 [95% CI, 1.28-4.33]; RD, 0.72% [95% CI, 0.26-1.18]), SHPT (HR, 2.85 [95% CI, 1.94-5.48]; RD, 1.33% [95% CI, 0.91-1.85]), and hypophosphatemia (HR, 1.96 [95% CI, 1.30-3.38]; RD, 0.85% [95% CI, 0.33-1.38]), which occurred mainly within the first 2 weeks of treatment. Adverse event rates were greater with lower kidney function and mainly limited to people with eGFR < 60 mL/min/1.73 m2. The denosumab-associated absolute risk differences for hypocalcemia (RD, 2.12% versus 0.19%; P for interaction = 0.04) and SHPT (RD, 4.84% versus 0.03%; P for interaction < 0.001) were greater in patients with eGFR < 60 versus ≥60 mL/min/1.73 m2. For hypophosphatemia, the RDs were numerically higher, but no multiplicative interaction was observed across lower eGFR strata (P for interaction = 0.1). The results were similar when restricting previous users of oral bisphosphonates, when requiring sustained abnormal laboratory values, and across different testing rate scenarios. LIMITATIONS: Residual confounding inherent to observational studies and lack of generalizability to other populations. CONCLUSIONS: Compared with zoledronate, denosumab was associated with higher risks of hypocalcemia, SHPT, and hypophosphatemia, particularly among users with moderate-to-advanced CKD, highlighting the need for careful monitoring of these parameters, especially immediately after treatment initiation. PLAIN-LANGUAGE SUMMARY: Denosumab is a drug used to prevent fractures, but it can affect calcium, phosphate, and parathyroid hormone levels in the blood. We studied adults aged 50 years or older in Stockholm, Sweden, to examine whether these risks differ by kidney function. Compared with zoledronate, denosumab was associated with higher risks of low calcium, low phosphate, and high parathyroid hormone levels. These adverse events occurred mainly within the first 2 weeks after starting treatment and were largely limited to people with moderate to advanced chronic kidney disease. Our findings suggest that patients with chronic kidney disease treated with denosumab should receive careful monitoring of mineral and hormone levels, especially at treatment initiation.
引用
- Xiao R, Faucon AL, He N, et al. Risks of Hypocalcemia and Other Bone Mineral Disorders for Denosumab Versus Zoledronate Across the Spectrum of Kidney Function: A Target Trial Emulation. Am J Kidney Dis. 2026. PMID: 42009245. doi:10.1053/j.ajkd.2026.02.642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。